Axon ID |
Name |
Description |
From price |
1398
|
Sunitinib malate
|
Multi-targeted receptor tyrosine kinase inhibitor |
€80.00 |
1411
|
Vandetanib
|
VEGFR and EGFR tyrosine kinase inhibitor |
€50.00 |
1414
|
AG 013736
|
PDGFR,c-KIT and VEGFR tyrosine kinase inhibitor |
€50.00 |
1420
|
Pazopanib hydrochloride
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€60.00 |
1461
|
Cediranib
|
VEGFR tyrosine kinase inhibitor |
€70.00 |
1547
|
OSI 930
|
c-Kit and VEGFR2 tyrosine kinase inhibitor |
€90.00 |
1637
|
Vatalanib
|
VEGFR tyrosine kinase inhibitor |
€75.00 |
1638
|
ABT 869
|
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor |
€85.00 |
1653
|
AEE 788
|
EGFR, ErbB2 and VEGFR tyrosine kinase inhibitor |
€80.00 |
1662
|
CP 547632
|
VEGFR2 tyrosine kinase inhibitor |
€70.00 |
1678
|
Regorafenib
|
Multi-kinase RTK inhibitor |
€70.00 |
1717
|
Tivozanib
|
VEGFR1, 2, and 3 tyrosine kinase inhibitor |
€80.00 |
1768
|
AMG 706
|
Multiple receptor tyrosine kinase inhibitor |
€105.00 |
1819
|
Cabozantinib S-malate
|
Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2 |
€60.00 |
1850
|
BMS 540215
|
Inhibitor of VEGFR (subtype 2 and 3 selective) |
€110.00 |
1864
|
Brivanib alaninate
|
Prodrug of BMS 540215; Inhibitor of VEGF |
€90.00 |
1891
|
SU 6668
|
Inhibitor of RTK targeting PDGFR, VEGF and FGFR |
€100.00 |
1942
|
E 3810 dihydrochloride
|
Dual VEGFR/FGFR tyrosine kinase inhibitor |
€90.00 |
1959
|
Golvatinib
|
Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2 |
€90.00 |
1963
|
LY 573636
|
Anti-tumor agent; causes growth arrest and apoptosis |
€80.00 |
1978
|
ZM 323881 hydrochloride
|
Inhibitor of VEGFR2 |
€105.00 |
2023
|
PF 03814735
|
ATP-competitive inhibitor of aurora kinase A and B |
€120.00 |
1667
|
SU 5402
|
Fibroblast growth factor receptor (FGFR) inhibitor |
€60.00 |
5006
|
Stem Cell CSD inhibitor Set
|
Set of CHIR99021, SU5402, and DAPT, inhibitors of GSK-3, FGFR, and γ-secretase, resp. |
€140.00 |
5007
|
Stem Cell 5i inhibitor Set
|
Set of five inhibitors for neural differentiation of human pluripotent stem cells. |
€200.00 |
2648
|
Nintedanib
|
RTK inhibitor with antiangiogenic and antineoplastic activities |
€70.00 |
2767
|
SU11652
|
Multi-targeted receptor tyrosine kinase inhibitor |
€140.00 |
2849
|
Apatinib
|
Inhibitor of VEGFR2 |
€120.00 |
2865
|
NVP-ACC789
|
Inhibitor of VEGFR2 |
€90.00 |
3624
|
Toceranib phosphate
|
Multi-targeted receptor tyrosine kinase inhibitor |
€60.00 |
3946
|
Altiratinib
|
Balanced inhibitor for MET, TIE2 (TEK), and VEGFR2 (KDR) kinases |
Inquire |
3975
|
MGCD265 dihydrochloride
|
Orally active, potent MET/SMO dual inhibitor |
€130.00 |
3998
|
MGCD516
|
Orally bioavailable receptor tyrosine kinase (RTK) inhibitor |
Inquire |
4073
|
CYC-116
|
Aurora kinases A & B and VEGFR2 inhibitor |
Inquire |